As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
DMPK or Drug Metabolism and Pharmacokinetics is a major part of studies related to drugs often referred to as ADME (Absorption, Distribution, Metabolism and Elimination). It is concerned with the study of aspects of absorption, distribution, metabolism and elimination of drug compounds which are administered through any route of administration.
Drug Metabolish and Pharmacokinetics are specific to drug discovery; drug properties such as route of administration, dose level, dose regimen and formulation, drug-drug interactions and specific populations are all tightly related to DMPK and are therefore measured by our experts. Our DMPK Department is dedicated to the understanding of the absorption, distribution, metabolism and excretion of drug candidates.
Medicilon’s pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody. The animal species involved in our DMPK cro services are non-human primate, canine, mice, rat, rabbit and hamster. Meanwhile, non-human primate experimental platform and isotope platform for protein/antibody are certified by the Shanghai Government.
Available studies include:
Method development and validation (GLP & Non-GLP)
Pharmacokinetics (Tumor bearing rodents, Bioavailability, Crossover studies, Cassette (N in 1) dosing and analysis, effects of gender on pharmacokinetics, BBB penetration )
Stability in vehicles and plasma
Drug interaction studies
In vitro metabolic stability
Prediction and identification of major metabolites
Distribution studies
Pharmacokinetics Package for IND Filing
DMPK package for CFDA and FDA IND filing
Chemical Compounds
Traditional Chinese Medicine
Protein
Antibody
Metabolic Stability Services
CYP Reaction Phenotyping
Microsomal Stability
S9 Stability
Hepatocyte Stability
Plasma Stability
Metabolite Profiling & Identification
Drug-Drug Interaction Services
Cytochrome P450 and UGT Reaction Phenotyping
Hepatocyte Induction
Cytochrome P450 Inhibition
Time Dependent Inhibition (Single Point)
Permeability and Transporter Services
Caco-2 Permeability
P-gp Inhibition
DMPK: Available reaction phenotyping services include:
Phase I:
Cytochrome P450 Enzymes (CYP)
Phase II:
UDP-glucuronyltransferases (UGT)
Metabolic Stability
Microsomes stability
Hepatocytes stability
Plasma stability
S9 stability
Protein Binding Services
Plasma Protein Binding
Brain Tissue Binding
Whole Blood Binding
Blood to Plasma Ratio
In vitro DMPK
High quality ADME data is essential to identify and help to address issues rapidly and early in the drug discovery, lead validation and optimization processes. The in vitro ADME service offers a portfolio of assays for investigating physicochemical properties, permeability, metabolism, drug-drug interactions (CYP inhibition, induction and phenotyping) and protein binding. These assays are offered either as a standalone services or to support our client sponsored medicinal chemistry programs.
In Vivo Pharmacokinetics
We can perform in vivo animal pharmacokinetic (PK) and other ADME studies in mice and rats in our CPCSEA approved AAALAC-accredited animal facility. We have a third party collaboration (CPCSEA approved facility) to perform pharmacokinetic studies in dogs.
A quantitative measure of drug exposure is necessary in order to interpret preclinical efficacy and toxicity studies. In a typical animal PK study, blood samples are obtained from animals at different time points following a single dose of a test compound. Plasma is harvested and subjected to bioanalysis. In an absolute bioavailability study of an orally administered drug, both oral and IV PK has to be performed. Relative oral bioavailability studies with different formulations can be carried out to enable selection of appropriate preclinical formulation for any compound. In toxicology studies, a satellite toxicokinetics group is included so as to assess the NOAEL (No Observable Adverse Effect Level) for any compound.
Email : marketing@medicilon.com
Tel : +86 021 58591500
Tips : Above is part of Drug Metabolism and Pharmacokinetics , DMPK cro studies , DMPK assays. You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.
Medicilon Drug Metabolite Analysis Service
Factors Affecting Pharmacokinetics of Drugs
In Vitro Drug Metabolism Studies Services
Drug Metabolism Test of Medicilon